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Abstract
Background Studies have evaluated the effect of thy-
roidectomy on the course of Graves’ ophthalmopathy (GO)
but it is unclear how GO as an indication might affect
surgical outcomes. We aimed to evaluate the impact of this
indication on surgical outcomes in Graves’ disease (GD).
Methods From 1995 to 2008, 329 patients with GD
underwent thyroidectomy. Patients were stratiﬁed into two
groups, namely, those with GO as indication (GO) and
those with non-GO indication (non-GO). Outcomes were
compared between the groups and outcomes with signiﬁ-
cance were further analyzed by multivariate analyses to
determine independent factors.
Results The GO group was signiﬁcantly older (P\
0.001), had more males (P\0.001), and fewer relapses
(P\0.001) than the non-GO group. It also had a higher
proportion of total/near-total thyroidectomy (P\0.001),
despite a shorter operating time (P = 0.024) and less blood
loss (P = 0.010). When only total/near-total thyroidec-
tomy was considered, the GO group had signiﬁcantly more
permanent hypoparathyroidism than the non-GO group
(9.2 vs. 1.6%, P = 0.038), but the rate of permanent
hypoparathyroidism was similar in the two groups when
only those with parathyroid autotransplantation were con-
sidered. Other complications were similar between the two
groups. By multivariate analysis, GO as indication was an
independent risk factor for temporary (OR 1.97,
P = 0.033) and permanent hypoparathyroidism (OR 4.76,
P = 0.007).
Conclusion GO as a surgical indication (i.e., unstable or
active GO requiring ophthalmic treatment or follow-up)
was associated with increased risk of temporary and per-
manent hypoparathyroidism after bilateral thyroidectomy.
Routine parathyroid autotransplantation may reduce the
risk of permanent hypoparathyroidism in this select patient
group.
Introduction
Graves’ disease (GD) is an autoimmune thyroid disease
with an unpredictable clinical course. It is caused by thy-
roid receptor antibodies that activate the thyrotrophin
(TSH) receptor leading to stimulation of cyclic adenosine
monophosphate synthesis and production of thyroid hor-
mones in the follicular cells [1, 2]. Treatment options
include antithyroid drugs (ATD), radioactive iodine ther-
apy (RAI), and thyroidectomy. In Europe and Asia, ATD is
the ﬁrst-line therapy, with RAI and thyroidectomy reserved
as second-line in case of relapse, whereas in the United
States, ATD is commonly used as an adjunct before RAI or
thyroidectomy [3–5]. Our institution has adopted the for-
mer approach with satisfactory surgical outcomes [6].
However, the actual decision for RAI or thyroidectomy in
relapsed cases remains controversial and depends on the
presence of absolute or relative surgical indication(s).
Graves’ ophthalmopathy (GO) is one of the accepted
indications but is considered a relative rather than an
absolute indication for thyroidectomy. Advantages of thy-
roidectomy over RAI in GO include a rapid and durable
control of hyperthyroidism and a potential for reversing
proptosis, eyelid width, and diplopia [7]. Furthermore, RAI
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are omitted [8]. Although numerous studies have demon-
strated the potential beneﬁts of thyroidectomy in GO [7, 9–
11], GO remains a relative surgical indication and it is still
unclear how GO as an indication might affect surgical
outcomes in GD. Most would presume that surgical out-
comes are similar to other non-GO indications as the same
procedure is performed. However, there is emerging evi-
dence that patients with GO tend to have more active
glandular disease and are more likely to relapse [12, 13].
Furthermore, one study has found that patients with severe
GO are signiﬁcantly more likely to suffer from both tem-
porary and permanent hypoparathyroidism after bilateral
thyroidectomy than those without GO (P = 0.004),
although the exact mechanism remains unexplained [13].
The aim of this study was to evaluate the impact of GO as
an indication relative to other accepted indications on the
surgical outcomes of thyroidectomy for GD. Primary out-
comes measured included recurrent laryngeal nerve injury,
hypoparathyroidism, postoperative bleeding, and wound
infection. Perhaps a better understanding might alter our
decision on the extent of thyroid resection, intraoperative
strategy, and perioperative management in this select group
of patients.
Patients and methods
From January 1995 to December 2008, 329 consecutive
patients undergoing thyroidectomy for GD were reviewed
and analyzed. Surgical techniques and perioperative man-
agement remained similar regardless of surgical indication.
The main indication or reason for choosing surgery over
RAI was recorded. Patients with symptoms or signs of GO
were assessed by independent ophthalmic assessment.
Only those with unstable or active GO requiring ophthal-
mic treatment or follow-up before thyroidectomy were
regarded as having GO as a surgical indication. Those with
stable or inactive GO not requiring treatment or follow-up
were not regarded as having GO as a surgical indication
and their indication was categorized in the same way as
those with no GO. If a patient had no clear surgical indi-
cation but expressed preference for surgery over RAI, it
was regarded as patient preference. However, if a patient
had no indication and did not express preference for sur-
gery, it was regarded as undocumented.
Table 1 shows the baseline patient characteristics and sur-
gical indications. There were 57 (17.3%) males and 272
(82.7%) females. The median (range) age at operation was
30 years (14–75). Eight (2.4%) patients had previous radio-
iodine therapy before thyroidectomy. Seventy-six (23.1%)
patients had GO as surgical indication. Among the non-GO
indications, patient preference (33.7%) was the most common.
The treatment strategy for GD remained the same
throughout the entire study period. The ﬁrst-line treatment
was 18 months of ATD (either carbimazole or propylthi-
ouracil). Beta-blocker agents were used for symptomatic
control. A relapse was deﬁned as a recurrence of hyper-
thyroidism after 18 months of ATD. Relapsed patients
were given the option of RAI or surgery unless surgery was
absolutely indicated, such as for those with suspected
malignancy or pressure symptoms. To evaluate the effect
GO as an indication on surgical outcomes in GD, patients
were stratiﬁed into two groups, GO group (patients with
GO as surgical indication, n = 76) and non-GO group
(patients with surgical indication other than GO, n = 253)
and their surgical outcomes were compared.
For preoperative preparation, all patients were pre-
scribed ATD to achieve euthyroidism before surgery. Beta-
blocker agents were prescribed for symptomatic control.
Lugol solution was not routinely administered. Subtotal
thyroidectomy was the preferred procedure before the year
2000. After that, total thyroidectomy became the preferred
procedure. Reasons for the change in surgical approach
were previously described [6]. Subtotal thyroidectomy was
deﬁned as resection that leaves up to 2–3 g of thyroid
remnant on either one side or both sides and near-total
thyroidectomy was resection that leaves less than 1 g of
remnant behind. Surgical techniques and postoperative care
had been previously described [14]. In brief, thyroidectomy
was performed through a collar incision with the patient
under general anesthesia and with endotracheal intubation.
The strap muscles were separated in the midline and
Table 1 Baseline patient characteristics and surgical indications (No.
of patients = 329)
Age at operation (years) 30 (14–75)
Gender
Male 57 (17.3)
Female 272 (82.7)
Previous RAI therapy prior to surgery 8 (2.4)
Number of relapses prior to surgery 1 (0–5)
Duration of antithyroid medications (months) 18 (0–90)
Duration of follow-up (months) since surgery 72 (6–169)
Surgical indications
Graves’ ophthalmopathy 76 (23.1)
Non-Graves’ ophthalmopathy indications
Patient preference 111 (33.7)
Patient refusal for radioiodine therapy 48 (14.6)
Large goiter with pressure symptoms 48 (14.6)
Suspicious of malignancy 16 (4.9)
Young age/planning pregnancy 23 (7.0)
Undocumented 7 (2.1)
Continuous data are expressed as median with range in parenthesis,
unless otherwise indicated
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123retracted laterally. Both recurrent laryngeal nerves (RLNs)
and parathyroid glands were routinely identiﬁed and pre-
served. Parathyroid glands that were inadvertently removed
or devascularized were immediately minced and autoim-
planted into the ipsilateral sternocleidomastoid muscle. A
wound drain was inserted selectively at the discretion of
the operating surgeon.
Serum calcium and phosphate levels were measured
within 6 h and every 12 h after surgery until stabilization.
Calcium supplements with or without vitamin D analog
were prescribed for those with symptomatic hypocalcemia
or a serum calcium level \1.70 mmol/l (normal ran-
ge = 2.11–2.55 mmol/l). Those who could discontinue
calcium plus vitamin D analog supplement in the presence
of normocalcemia within 12 months after surgery were
categorized as having temporary hypoparathyroidism and
those who had to continue for [12 months and had a
below-normal serum parathyroid hormone level (normal
range = 11–54 pg/ml) were categorized as having perma-
nent hypoparathyroidism. Oral thyroxine supplement was
given on the day of discharge for hormonal replacement
depending on the age and body weight of the patient.
Perioperative direct laryngoscopy was performed rou-
tinely before and within 1 week after the operation to assess
vocal cord function. RLN palsy lasting more than 6 months
after thyroidectomy as documented by direct laryngoscopy
was regarded as permanent. To calculate the transient and
permanent RLN palsy rates, the number of nerves at risk
was used. There was no patient with preoperative cord palsy
or who needed the RLN intentionally sacriﬁced at operation.
The total number of nerves at risk was 658 (i.e., 329 9 2).
All patients were regularly followed up 2 weeks after sur-
gery, every 3–6 months for ﬁrst 2 years, and yearly there-
after. All relevant clinical, laboratory, radiologic, and
perioperative data were collected prospectively and follow-
up data were regularly updated in a computerized database.
Statistics
The statistical analysis was performed using the SPSS ver.
18.0 (SPSS, Inc., Chicago, IL, USA). A v
2 test and Fisher’s
exact test were used for comparison of dichotomous vari-
ables, and the Mann-Whitney U test was used for com-
parison of continuous variables between the GO and non-
GO groups. Outcomes that were signiﬁcant were further
analyzed in a multivariate analysis by logistic regression to
determine independent risk factors. To improve clinical
utility, before entering into the multivariate analysis, sig-
niﬁcant continuous variables were converted into binary
variables using the overall median value as the cutoff. A
binary logistic regression analysis was used in multivariate
analysis in order to identify independent factors. A
P value\0.05 was considered statistically signiﬁcant.
Results
Table 2 shows a comparison of patient demographics,
operative ﬁndings, type of resection, and histological
ﬁndings between the GO and non-GO groups. The GO
group was older in median age (36 vs. 30 years,
P\0.001) and had a greater proportion of males than the
non-GO group (32.9 vs. 12.6%, P\0.001). However, the
GO group had signiﬁcantly fewer relapses prior to surgery
than the non-GO group (0 vs. 1, P\0.001). There was a
greater proportion of patients who underwent total or near-
total thyroidectomy in the GO group (80.3 vs. 59.7%,
P = 0.001), but the volume of blood loss was less (50 vs.
80 ml, P = 0.010) and the operating time was shorter in
the GO group (139 vs. 150 min, P = 0.024). The excised
gland was lighter in the GO group (46 vs. 54 g,
P = 0.004). There were a greater number of parathyroid
glands identiﬁed per procedure in the GO group (4 vs. 3,
P = 0.023), but the number of glands transplanted and rate
of transplantation appeared similar between the groups.
Histological ﬁndings were similar for the two groups.
Table 3 shows a comparison of short- and long-term
surgical outcomes between the GO and non-GO groups.
There was signiﬁcantly more temporary hypoparathyroid-
ism (32.9 vs. 20.2%, P = 0.021) and permanent hypo-
parathyroidism (9.2 vs. 2.8%, P = 0.015) in the GO group.
When only total or near-total versus subtotal thyroidec-
tomy was considered, the GO group was signiﬁcantly more
likely to suffer permanent hypoparathyroidism than the
non-GO group (9.2 vs. 1.6%, P = 0.038). When patients
were stratiﬁed according to whether parathyroid auto-
transplantation was performed, the rate of permanent
hypoparathyroidism was signiﬁcantly higher in the GO
group than in the non-GO group when parathyroid auto-
transplantation was not performed (P = 0.032), whereas
the rate was similar when parathyroid autotransplantation
was performed (P = 0.338). There was no signiﬁcant dif-
ference in other surgical complications, including vocal
cord palsy, postoperative bleeding, postoperative infection,
and length of hospital stay. In the subtotal thyroidectomy
group, after a median follow-up of 107.2 months, there
were 10 (8.5%) patients who suffered persistent or recur-
rent GD; 5 required additional RAI therapy while the other
5 decided to resume ATD. Two of the ﬁve patients who
received RAI eventually became hypothyroid and required
thyroxine replacement. In the total or near-total thyroid-
ectomy group, after a median follow-up of 48.7 months, no
patient developed recurrent GD or required ATD or RAI.
Therefore, the overall rate of persistent or recurrent GD in
subtotal thyroidectomy was 10/117 (8.5%). Of the 117
subtotal thyroidectomies performed, only 23 (19.7%)
patients maintained normal thyroid function not requiring
daily thyroxine replacement therapy.
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123To determine independent risk factors for postopera-
tive hypoparathyroidism, age at operation, gender,
number of relapses, type of resection, operating time
[150 min, weight of gland [52 g, parathyroid auto-
transplantation, and GO as an indication were analyzed.
Gender, type of operation, parathyroid autotransplanta-
tion and GO turned out to be signiﬁcant in univariate
analysis (not shown) but on multivariate analysis, only
female gender (OR 2.77, 95% CI: 1.14–6.73, P = 0.024),
total or near-total thyroidectomy (OR 2.44, 95% CI:
1.31–4.56, P = 0.005), and GO as indication (OR 1.97,
95% CI: 1.06–3.66, P = 0.033) turned out to be inde-
pendent risk factors for temporary hypoparathyroidism
(see Table 4). For permanent hypoparathyroidism, oper-
ating time [150 min (OR 10.02, 95% CI: 2.65–37.91,
P = 0.001) and GO as indication (OR 4.76, 95% CI:
1.52–14.88, P = 0.007) were independent risk factors
(see Table 5).
Table 2 A comparison of
patient demographics, operative
ﬁndings, type of resection, and
histological ﬁndings between
patients with Graves’
ophthalmopathy as indication
(GO group) and patients with
other indications (non-GO
group)
Continuous data are expressed
as median with range in
parenthesis, unless otherwise
indicated
GO Graves’ ophthalmopathy,
FTC follicular thyroid cancer,
PTC papillary thyroid cancer
Bold indicates P value\0.05 as
statistical signiﬁcance
GO (n = 76) Non-GO (n = 253) P value
Age at operation (years) 36 (18–75) 30 (14–73) <0.001
Gender (male:female) 25:51 32:221 <0.001
Family history 11 (16.7) 51 (23.7) 0.190
Previous radioiodine therapy 3 (3.9) 5 (2.0) 0.328
Number of relapses 0 (0–5) 1 (1–5) <0.001
0 34 (44.7) 38 (15.0)
1 17 (22.4) 74 (29.2)
C2 16 (21.1) 104 (41.1)
Operating time (min) 139 (75–215) 150 (60–360) 0.024
Blood loss (ml) 50 (0–300) 80 (0–140) 0.010
Weight of excised gland (g) 46 (6–240) 54 (6–727) 0.004
Type of resection 0.001
Subtotal thyroidectomy 15 (19.7) 102 (40.3)
Total or near-total thyroidectomy 61 (80.3) 151 (59.7)
No. of parathyroid glands identiﬁed per operation 4 (0–4) 3 (0–4) 0.023
No. of parathyroid glands autotransplanted per operation 1 (0–2) 1 (0–3) 0.876
Parathyroid autotransplantation 37 (50.7) 126 (50.6) 0.990
Histological ﬁndings
Diffuse hyperplasia 71 (93.4) 245 (96.8) 0.882
Diffuse hyperplasia with occult PTC 4 (5.3) 7 (2.8) 0.270
Diffuse hyperplasia with occult FTC 1 (1.3) 1 (0.4) 0.410
Concomitant autoimmune thyroiditis 7 (13.5) 20 (15.0) 0.785
Table 3 A comparison of
primary postsurgical outcomes
between patients with Graves’
ophthalmopathy as indication
(GO) and those with other non-
GO indications (non-GO)
Continuous data are expressed
as median with range in
parenthesis, unless otherwise
indicated
a Calculated based on total
number of nerves at risk
Bold indicates P value\0.05 as
statistical signiﬁcance
Postoperative outcome GO (n = 76) Non-GO (n = 253) P value
Hospital stay (days) 3 (1–7) 3 (1–11) 0.232
Temporary hypoparathyroidism 25 (32.9) 51 (20.2) 0.021
Subtotal thyroidectomy 0/15 (0.0) 21/102 (20.6) 0.629
Total or near-total thyroidectomy 25/61 (41.0) 30/151 (19.9) 0.073
Permanent hypoparathyroidism 7 (9.2) 7 (2.8) 0.015
Subtotal thyroidectomy 0/15 (0.0) 3/102 (2.9) 0.763
Total or near-total thyroidectomy 7/61 (11.5) 4/151 (2.6) 0.038
Permanent hypoparathyroidism 7 (9.2) 7 (2.8)
With parathyroid autotransplantation 2/35 (5.7) 3/126 (2.4) 0.338
Without parathyroid autotransplantation 5/41 (12.2) 4/127 (3.1) 0.032
Vocal cord palsy—temporary
a 2 (1.3) 6 (1.2) 0.970
Vocal cord palsy—permanent
a 0 (0.0) 2 (0.4) 0.420
Postoperative bleeding 1 (1.4) 6 (2.4) 0.595
Wound infection 0 (0.0) 1 (0.4) 0.588
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The general management of GD remains controversial. The
issue of whether ATD, RAI, or surgery should be used has
long been debated and the decision varies greatly
depending on different parts of the world [3]. For those
with relapsed GD after an adequate course of ATD, the
decision for either RAI or thyroidectomy mostly depends
on the presence of absolute or relative surgical indication.
Thyroidectomy has gained an increasing role over RAI in
relapsed GD as it offers more rapid and lasting control of
the hyperthyroidism, and for those with preexisting GO, it
could also possibly reverse a certain degree of proptosis,
eyelid width, and diplopia [7, 9–11]. In contrast to previous
studies that evaluated the effect of thyroidectomy on GO,
the aim of the present study was to evaluate whether GO,
which remains a relative surgical indication, would affect
surgical outcomes in GD. We postulated that GO as an
indication might adversely affect outcomes as the disease is
generally more active and severe, making the surgery more
technically demanding [12, 13]. Furthermore, a study has
found that patients with severe GO are more likely to suffer
from hypoparathyroidism after thyroidectomy [13]. Since
GO is common and is present in about a third of patients
with GD [15], the present analysis regarded only patients
with active or unstable GO requiring ophthalmic treatment
or follow-up as having a genuine indication for thyroid-
ectomy. Those with stable GO not requiring treatment or
follow-up were not regarded as having GO as a surgical
indication and their indications were categorized in the
same way as those without GO.
The present analysis comprised two parts. The ﬁrst part
was to evaluate whether there were differences in outcomes
between the GO and non-GO groups. Our data showed that
the GO group had a signiﬁcantly shorter operating time,
less blood loss, and lighter excised thyroid gland weight.
These ﬁndings are consistent with our previous observation
that there was an increasing number of patients with GO
undergoing thyroidectomy recently [16], and we believed
the shorter operating time and less blood loss were a result
of the surgical technical improvements and not a result of
GO per se. The gland weight of the excised thyroid was
lighter in the GO group because GO was a result of the
autoimmune cross-activity between the thyroid and orbital
antigens and not related to the gland size [13]. The data
showed that the GO group was signiﬁcantly more likely to
suffer both temporary and permanent hypoparathyroidism
after bilateral thyroidectomy than the non-GO group, even
though the overall rate of hypoparathyroidism was com-
patible to those of other studies [17–19]. The risk of other
complications was not signiﬁcantly different between the
two groups. When the extent of surgery (i.e., total or near-
total vs. subtotal thyroidectomy), a well-known factor for
hypoparathyroidism [20], was adjusted between the two
groups, the GO group still had a signiﬁcantly higher risk of
permanent hypoparathyroidism than the non-GO group
(9.2 vs. 1.6%). This was despite the fact that there were a
greater number of parathyroid glands identiﬁed in the GO
group and a similar proportion of parathyroid autotrans-
plantations performed at the time of operation in the two
groups. Interestingly, both the number of parathyroid
glands identiﬁed and parathyroid autotransplantation were
shown to reduce the rate of permanent hypoparathyroidism
in thyroidectomy [21–23]. This was supported by the
subgroup analysis when patients were stratiﬁed according
to whether parathyroid autotransplantation was performed
or not. Our data showed that the permanent hypoparathy-
roidism rate was similar between the GO and non-GO
groups when parathyroid autotransplantation was per-
formed. In fact, the rate of permanent hypoparathyroidism
was reduced from 12.2 to 5.7% in the GO group. To further
determine if GO as a surgical indication was an indepen-
dent factor for temporary and permanent hypoparathy-
roidism, two multivariate analyses were done. In
concordance with the ﬁrst part of the analysis, GO as a
surgical indication turned out to be an independent factor
for both temporary and permanent hypoparathyroidism.
Female gender and extent of resection were the other
independent risk factors for temporary hypoparathyroid-
ism, and operating time[150 min was the other indepen-
dent risk factor for permanent hypoparathyroidism. All of
these factors, with the exception of operating time, were
previously reported to be risk factors [21–25]. The authors
believed the length of operating time was a possible
Table 4 A multivariate analysis of factors leading to temporary
hypoparathyroidism after thyroidectomy in Graves’ disease
Odds ratio 95% CI P value
Female gender 2.77 (1.14–6.73) 0.024
Total or near-total
thyroidectomy
2.44 (1.31–4.56) 0.005
Parathyroid autotransplantation 1.69 (0.98–2.91) 0.060
Graves’ ophthalmopathy as a
surgical indication
1.97 (1.06–3.66) 0.033
Bold indicates P value\0.05 as statistical signiﬁcance
Table 5 A multivariate analysis of factors leading to permanent
hypoparathyroidism after thyroidectomy in Graves’ disease
Odds ratio 95% CI P value
Operating time[150 min 10.02 2.65–37.91 0.001
Graves’ ophthalmopathy
as surgical indication
4.76 1.52–14.88 0.007
Bold indicates P value\0.05 as statistical signiﬁcance
2216 World J Surg (2011) 35:2212–2218
123surrogate marker of the degree of technical difﬁculty with
the procedure.
There are a number of possible explanations for the
higher incidence of hypoparathyroidism in GO after bilateral
thyroidectomy. First, those with GO tend to have more
active glandular disease than those without GO as indicated
by the higher level of TSH-receptor auto-antibodies present
[26, 27]. This higher glandular activity could possibly
translate into increased adhesions between the thyroid and
parathyroids and microvessel density on the thyroid gland
making the subcapsular dissection and preservation of the
parathyroid glands and their blood supply technically more
difﬁcult for the surgeon. Since the number of parathyroid
glands identiﬁed was actually higher in the GO group than in
the non-GO group, it was not related to identifying the
parathyroids but rather related to preserving the blood sup-
ply to the parathyroids. The second explanation for the
higher incidence of hypoparathyroidism in GO might be
related to the phenomenon of ‘‘hungry bone’’ syndrome after
surgery as reported previously in GD after thyroidectomy
[25]. Perhaps patients with active GO might have a more
severe form of hungry bone syndrome. However, this would
explain only the higher postoperative temporary hypopara-
thyroidism and not the permanent hypoparathyroidism.
Perhaps a postoperative PTH level would help to distinguish
hungry bone syndrome from temporary hypoparathyroidism.
We believe that a number of strategies could be adopted
in the future to reduce hypoparathyroidism. First, for
patients with GO undergoing thyroidectomy, perhaps less
resection such as a subtotal thyroidectomy could be con-
sidered. In our subgroup analysis, it was interesting to note
that no patient suffered permanent hypoparathyroidism
after subtotal thyroidectomy in the GO group. However,
one must also consider the long-term problem of relapse
and delayed hypothyroidism associated with subtotal thy-
roidectomy [6]. The other strategy would be to increase the
proportion of parathyroid autoimplantation. Instead of
practicing selective parathyroid autoimplantation, which in
our series amounted to 51%, routine or 100% autoim-
plantation of at least one viable parathyroid gland during
surgery might be a better strategy in patients with GO.
Also, given the relatively high incidence of temporary
hypoparathyroidism (41.0%), patients with GO as a sur-
gical indication undergoing a total thyroidectomy might
perhaps beneﬁt from routine administration of calcium and
vitamin D supplementation to reduce the risk of symp-
tomatic postoperative hypocalcemia.
The limitations of this study included the retrospective
nature of data analysis and the fact that the data were
collected for a 14-year period so there might have been
subtle changes in referral pattern and practice contributing
to the higher incidence of hypoparathyroidism [16]. Also,
our study did not contain data on thyroid-stimulating
hormone receptor (TSHR), which is an important marker
for the severity of GD, so our proposal of more active
disease in the GO group was based purely on our clinical
and operative observations. Data on postoperative para-
thyroid hormone and vitamin D levels were not available
and would have been useful in providing a better under-
standing of the cause of postoperative hypoparathyroidism.
As vitamin D deﬁciency is prevalent in our geographical
area, this could have also contributed to the rate of tem-
porary hypoparathyroidism in the two groups [28]. Further
studies focusing on the dynamics of vitamin D and its
relation to hypoparathyroidism in GD and GO might prove
fruitful. Also, it would have been interesting to evaluate
any eye changes before and after total or near-total thy-
roidectomy or subtotal thyroidectomy in patients with
active GO.
Conclusion
GO as a surgical indication (i.e., unstable or active GO
requiring ophthalmic treatment or follow-up) was associated
with increased risk of temporary and permanent hypopara-
thyroidism after bilateral thyroidectomy. Routine or 100%
parathyroid autotransplantation may reduce the risk of per-
manent hypoparathyroidism in this select patient group.
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